DOYLESTOWN, Pa.--(BUSINESS WIRE)--QuantRx Biomedical Corporation (OTCBB: QTXB) announced today the creation of a joint venture with NuRx Pharmaceuticals, Inc. (OTCBB: NUXP) to accelerate efforts to capitalize opportunities in the fast growing market for Point-of-Care (POC) products. In addition to benefiting from the collaboration of executive management of the founding partner companies, NuRx has agreed to provide Portland, Oregon-based QN Diagnostics in excess of $5 million in cash for working capital to be used through the commercial launch and revenue generation of its innovative POC family of products.
